← Back to Search

Immunomodulatory Agent

Lenalidomide + Rituximab for Lymphoma

Phase 2

Waitlist Available

Led By Joseph M. Tuscano, MD

Research Sponsored by University of California, Davis

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Relapsed or refractory disease

Evidence of disease progression during or after last treatment

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to two years

Awards & highlights

Study Summary

This trial is studying lenalidomide and rituximab to see how well they work compared with rituximab in treating patients with follicular or small lymphocytic lymphoma.

Who is the study for?

This trial is for patients with specific types of non-Hodgkin lymphoma that have relapsed or didn't respond to treatment. Participants should be relatively healthy, not pregnant, and without serious recent cancers or neuropathy. They must have at least one measurable lesion and no CNS metastases, a decent performance status (ECOG 0-2), acceptable blood counts, organ function, and agree to use effective contraception.Check my eligibility

What is being tested?

The study tests the combination of lenalidomide (a drug that may stimulate the immune system) with rituximab (an antibody that blocks cancer growth) in treating lymphoma. It's a phase II trial aimed at seeing how well this combo works against follicular or small lymphocytic non-Hodgkin lymphoma after other treatments failed.See study design

What are the potential side effects?

Lenalidomide can cause side effects like fatigue, diarrhea, rash or itching; it might also affect blood cell counts leading to higher infection risk. Rituximab could cause infusion reactions such as fever and chills, body aches, tiredness; rarely severe skin reactions or heart problems may occur.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

My condition has returned or didn't respond to treatment.

Select...

My condition worsened during or after my last treatment.

Select...

I can take daily aspirin or low molecular weight heparin.

Select...

I do not have severe nerve pain or numbness.

Select...

I haven't had skin reactions from thalidomide or similar medications.

Select...

I do not have active hepatitis A, B, or C.

Select...

I can swallow lenalidomide pills.

Select...

I can take care of myself and am up and about more than half of the day.

Select...

My condition is a specific type of non-Hodgkin lymphoma.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to two years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to two years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to two years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Response, as defined by complete response (CR), near CR, partial response, or stable disease at 4 months

Secondary outcome measures

Duration of response

Overall survival

Time to disease progression

+1 more

Side effects data

From 2016 Phase 2 & 3 trial • 86 Patients • NCT03002038

Gastrointestinal intolerance

Impaired liver function test

100%

80%

60%

40%

20%

Study treatment Arm

Azathioprine

Rituximab

Trial Design

1Treatment groups

Experimental Treatment

Group I: Lenalidomide and RituximabExperimental Treatment2 Interventions

Rituximab 375 mg/m2/wk x 4 weeks, to begin Cycle 1, Day 15. Lenalidomide 20 mg daily, days 1-21 of a 28 day cycle, to begin Day 1 of cycle 1 and continue until disease progression.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Lenalidomide

2005

Completed Phase 2

~1070

Rituximab

1999

Completed Phase 4

~1880

0 / 9Eligibility criteria met

Find a Location

Who is running the clinical trial?

University of California, DavisLead Sponsor

914 Previous Clinical Trials

4,720,685 Total Patients Enrolled

9 Trials studying Lymphoma

735 Patients Enrolled for Lymphoma

CelgeneIndustry Sponsor

642 Previous Clinical Trials

130,543 Total Patients Enrolled

88 Trials studying Lymphoma

9,734 Patients Enrolled for Lymphoma

Joseph M. Tuscano, MDPrincipal InvestigatorUniversity of California, Davis

Media Library

Lenalidomide (Immunomodulatory Agent) Clinical Trial Eligibility Overview. Trial Name: NCT00848328 — Phase 2

Lymphoma Research Study Groups: Lenalidomide and Rituximab

Lymphoma Clinical Trial 2023: Lenalidomide Highlights & Side Effects. Trial Name: NCT00848328 — Phase 2

Lenalidomide (Immunomodulatory Agent) 2023 Treatment Timeline for Medical Study. Trial Name: NCT00848328 — Phase 2

~2 spots leftby Jun 2025

Unbiased ResultsWe believe in providing patients with all the options.

Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.

Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.